An Update on Nanocarriers for Follicular-Targeted Drug Delivery for Androgenetic Alopecia Topical Treatment
January 2025
in “
Expert Opinion on Drug Delivery
”
Studysummary This study discusses the limitations of current FDA-approved treatments for androgenic alopecia, noting significant sexual side effects with oral finasteride and formulation challenges with topical minoxidil, and highlights the potential of nanocarriers to improve drug delivery to hair follicles.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on tandfonline.com →